132 related articles for article (PubMed ID: 9589713)
1. Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
Lamberti G; Pignalosa B; Fusco R; Pignalosa G; Di Govanni A; Sebastiani A
Acta Ophthalmol Scand Suppl; 1997; (224):20-1. PubMed ID: 9589713
[No Abstract] [Full Text] [Related]
2. Pressure-reducing efficacy and tolerability of betaxolol in ionic solution.
Troiano P; Cavallotti B; Iraci M; Galli L; Miglior M
Acta Ophthalmol Scand Suppl; 1997; (224):18-20. PubMed ID: 9589712
[No Abstract] [Full Text] [Related]
3. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.
Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP
Am J Ophthalmol; 1995 Oct; 120(4):423-32. PubMed ID: 7573299
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Javitt J; Goldberg I
J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
[TBL] [Abstract][Full Text] [Related]
5. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Serle JB
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
[TBL] [Abstract][Full Text] [Related]
7. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
9. Effect of betaxolol on primary open-angle glaucoma and normal-tension glaucoma patients.
Saccà SC; Macrì A; Rolando M; Ciurlo G
J Ocul Pharmacol Ther; 1998 Jun; 14(3):191-201. PubMed ID: 9671427
[TBL] [Abstract][Full Text] [Related]
10. Short-term effect of apraclonidine on intraocular pressure in glaucoma patients receiving timolol and pilocarpine.
Yüksel N; Elibol O; Caglar Y; Alçelik T
Ophthalmologica; 1997; 211(6):354-7. PubMed ID: 9380353
[TBL] [Abstract][Full Text] [Related]
11. Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine.
Robin AL
Trans Am Ophthalmol Soc; 1996; 94():89-101; discussion 101-3. PubMed ID: 8981691
[TBL] [Abstract][Full Text] [Related]
12. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.
Weinreb RN; Caldwell DR; Goode SM; Horwitz BL; Laibovitz R; Shrader CE; Stewart RH; Williams AT
Am J Ophthalmol; 1990 Aug; 110(2):189-92. PubMed ID: 2198812
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.
Stewart WC; Ritch R; Shin DH; Lehmann RP; Shrader CE; van Buskirk EM
Arch Ophthalmol; 1995 Mar; 113(3):287-92. PubMed ID: 7887841
[TBL] [Abstract][Full Text] [Related]
14. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
[TBL] [Abstract][Full Text] [Related]
15. A comparative evaluation of pilocarpine 1% and clonidine 0.125% versus timolol 0.5%.
Sihota R; Agarwal HC; Rajashekar YL
Indian J Ophthalmol; 1996 Jun; 44(2):87-9. PubMed ID: 8916595
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of apraclonidine ophthalmic solution (iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
Flach AJ
Surv Ophthalmol; 1995; 40(1):84-5. PubMed ID: 8545811
[No Abstract] [Full Text] [Related]
17. Questions concerning the role of apraclonidine in the management of glaucoma.
Robin AL
Arch Ophthalmol; 1995 Jun; 113(6):712-4. PubMed ID: 7786208
[No Abstract] [Full Text] [Related]
18. Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
Nishimoto JH; Chang FW; Tang IH; Kolin T
J Am Optom Assoc; 1999 Apr; 70(4):233-9. PubMed ID: 10457699
[TBL] [Abstract][Full Text] [Related]
19. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.
Geyer O; Schmidt KG; Pianka P; Neudorfer M; Lazar M
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):149-52. PubMed ID: 10766284
[TBL] [Abstract][Full Text] [Related]
20. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
